1[1]Craig WA. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy[J]. Respir Med, 2001,95(Suppl A): 12-19
2[2]Frimodt-Moller N. How predictive is PK /PD for antibacterial agents[J]? Int J Antimicrob Agents, 2002,19: 333-339
3[3]Craig WA. Pharmacokinetic /pharmacodynamic parameters: rationale for antibacterial dosing of mice and men[J]. Clin Infect Dis, 1998,26:1-10
4[4]Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance[J]. Chest, 1999, 115(Suppl 3):19-23
5[5]Dagan R, Klugman KP, Craig WA, et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy[J]. J Antimocrob Chemother, 2001, 47:129-140
6[6]Cazzola M, Di Perna F, Boveri B, et al. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis[J]. J Chemother, 2000, 12:216-222
7[7]Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia[J]. Am J Med, 1984, 77:657-662
8[8]Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration[J].J Infect Dis, 1987,155:93-99
9[9]Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients[J]. Antimicrob Agents Chemother, 1993,37:1073-1081
10[10]Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy[J]. Antimicrob Agents Chemother, 1998, 42:521-527
